Point-of-Care Fluorescence Immunoassay for Cardiac Panel Biomarkers

Journal of Clinical Laboratory Analysis

Volumn 28, Issue 6, 2014, Pages 419-427

  Kim, Tae Kyum ^a,b   Oh, Sang Wook ^c   Hong, Soon Cheol ^b   Mok, Young Joon ^b   Choi, Eui Yul ^a,b  

^a Hallym University   (South Korea)

^b Boditech Med Inc   (South Korea)

^c Chonbuk National University   (South Korea)

Author keywords

AMI; CK MB; cTnI; fluorescence immunochromatographic assay; myoglobin; POCT

Indexed keywords

CREATINE KINASE MB; MYOGLOBIN; TROPONIN I;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CALIBRATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; POINT OF CARE TESTING; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RELIABILITY;

EID: 85006511364     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21704     Document Type: Article

References (26)

1. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013;127(3):e283–e352.
2. European Heart Rhythm A, European Society of C, Heart Rhythm S, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: Implant and follow-up recommendations and management. Heart Rhythm 2012;9(9):1524–1576.
3. Lefebvre CW, Hoekstra J. Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: Risk stratification and treatment strategies. Hosp Pract 2010;38(2):40–49.
4. Tiwari RP, Jain A, Khan Z, et al. Cardiac troponins I and T: Molecular markers for early diagnosis, prognosis, and accurate triaging of patients with acute myocardial infarction. Mol Diagn Ther 2012;16(6):371–381.
5. Friess U, Stark M. Cardiac markers: A clear cause for point-of-care testing. Anal Bioanal Chem 2009;393(5):1453–1462.
6. de Winter RJ, Koster RW, Sturk A, Sanders GT. Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. Circulation 1995;92(12):3401–3407.
7. Gruberg L, Sudarsky D, Kerner A, Hammerman H, Kapeliovich M, Beyar R. Troponin-positive, CK-MB-negative acute myocardial infarction: Clinical, electrocardiographic and angiographic characteristics. J Invasive Cardiol 2008;20(3):125–128.
8. Yang Z, Yamazaki M, Shen QW, Swartz DR. Differences between cardiac and skeletal troponin interaction with the thin filament probed by troponin exchange in skeletal myofibrils. Biophys J 2009;97(1):183–194.
9. Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Col Cardiol 2013;61(18):1906–1913.
10. Diercks DB, Peacock WF 4th, Hollander JE, et al. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain. Am Heart J 2012;163(1):74–80.
11. Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med 2010;8:34.
12. Lackner KJ. Laboratory diagnostics of myocardial infarction—Troponins and beyond. Clin Chem Lab Med 2013;51(1):83–89.
13. Ahn JS, Choi S, Jang SH, et al. Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. Clin Chim Acta 2003;332(1–2):51–59.
14. Kim BC, Jeong JH, Jeong DS, Choi EY, Kim JH, Nahm KB. Simplified laser fluorescence scanner for proteomics studies and early cancer diagnosis. Proc SPIE 2002;4916:103–108.
15. Bingisser R, Cairns C, Christ M, et al. Cardiac troponin: A critical review of the case for point-of-care testing in the ED. Am J Emerg Med 2012;30(8):1639–1649.
16. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355(25):2631–2639.
17. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358(20):2107–2116.
18. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;8(1):54–61.
19. Apple FS, Smith SW, Pearce LA, et al. Use of the bioMerieux VIDAS troponin I ultra assay for the diagnosis of myocardial infarction and detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chim Acta 2008;390(1–2):72–75.
20. Hofmann D, Buettner M, Rissner F, Wahl M, Sakka SG. Prognostic value of serum myoglobin in patients after cardiac surgery. J Anesth 2007;21(3):304–310.
21. Thygesen K, Mair J, Katus H, et al. Study group on biomarkers in cardiology of the ESCWGoACC. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010;31(18):2197–2204.
22. Yilmaz A, Yalta K, Turgut OO, et al. Clinical importance of elevated CK-MB and troponin I levels in congestive heart failure. Adv Ther 2006;23(6):1060–1067.
23. Panteghini M. The measurement of cardiac markers: Where should we focus? Am J Clin Path 2002;118(3):354–361.
24. Panteghini M, Pagani F, Yeo KT, et al. Committee on standardization of markers of cardiac damage of the TnI. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004;50(2):327–332.
25. Calzavacca P, Licari E, Tee A, Bellomo R. Point-of-care testing during medical emergency team activations: A pilot study. Resuscitation 2012;83(9):1119–1123.
26. McDonnell B, Hearty S, Leonard P, O'Kennedy R. Cardiac biomarkers and the case for point-of-care testing. Clin Biochem 2009;42(7–8):549–561.